Teva Pharmaceutical Industries Limited (T1EV34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 99.20 |
|---|---|
| 52-week range | 51.60 – 104.80 |
| Return, 1 month / 3 months | −1.4% / +27.3% |
| Return, 1 year / 3 years | +92.2% / +384.6% |
| Trend | Uptrend |
| RSI (14) | 50 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -21.6% |
| Average daily value traded | 0.01M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Teva Pharmaceutical Industries is a pharmaceutical company based in Israel that makes generic medicines, which are copies of branded drugs sold after the original patents expire. It supplies pharmacies, hospitals, health systems and other drugmakers with tablets, capsules, injectable products and active ingredients. The company also develops and markets specialty medicines in areas such as nervous system disorders and respiratory care, and it operates manufacturing and research sites in several countries.
Teva Pharmaceutical Industries Limited is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code T1EV34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Teva Pharmaceutical Industries Limited (T1EV34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 99.20 on 23 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 184 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 92.2% and over the last three months it rose 27.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.5% | ||
| From 52-week high | -5.3% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 27.3% | ||
| 6-month return | 28.4% | ||
| 12-month return, skipping the last month | 95.0% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.6% | ||
| Liquidity | 25 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M BRL | ||
| Zero-volume days | 61.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.3% |
|---|---|
| 1 month | −1.4% |
| 3 months | +27.3% |
| 6 months | +28.4% |
| 1 year | +92.2% |
| 3 years | +384.6% |
| 5 years | +246.2% |
Signals
| 50-day / 200-day average | 97.64 / 87.43 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.59 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.